Allarity Therapeutics, Inc.
ALLR$15M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaBOSTON6 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Mar 2027
Market Overview
Stock performance and key metrics
ALLR News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
2X-121
Advanced Ovarian Cancer
PARP inhibitor 2X-121
Metastatic Breast Cancer
Irofulven
Metastatic Castration-Resistant Prostate Cancer Patients
LiPlaCis
Phase 1: Advanced or Refractory Solid Tumours
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
2X-121 | Phase 2 | Advanced Ovarian Cancer | - | - |
PARP inhibitor 2X-121 | Phase 2 | Metastatic Breast Cancer | - | - |
Irofulven | Phase 2 | Metastatic Castration-Resistant Prostate Cancer Patients | - | - |
LiPlaCis | Phase 2 | Phase 1: Advanced or Refractory Solid Tumours | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply